

To: [redacted] [redacted] [redacted]@minvws.nl]
From: [redacted] [redacted]
Sent: Thur 8/20/2020 9:07:18 AM
Subject: FW: Presentation Veklury
Received: Thur 8/20/2020 9:07:19 AM

Ter info

Van: [redacted] [redacted]@rivm.nl>
Verzonden: donderdag 20 augustus 2020 10:42
Aan: [redacted]@ec.europa.eu' <[redacted] [redacted]>
 [redacted]@ec.europa.eu>
CC: [redacted] [redacted] <[redacted]@minvws.nl>; [redacted] [redacted] <[redacted]@minvws.nl>; [redacted] [redacted] <[redacted]@rivm.nl>
Onderwerp: RE: Presentation Veklury
Urgentie: Hoog

Dear colleagues,

Just now I have tried to join the audioconference, but I did not hear anything. I have gone through the slides and will provide answers to your questions later. However, I was surprised to see that on slide 3 The Netherlands is not mentioned as a participant. Yesterday we have provided both contact persons and needs analysis. Could you please confirm that The Netherlands is on the list?

Kind regards,

[redacted]

[redacted]

[redacted]

Department for Vaccine Supply and Prevention Programmes (RIVM-DVP)
National Institute for Public Health and the Environment
Ministry of Health, Welfare and Sport

A. van Leeuwenhoeklaan 9 | 3721 MA | Bilthoven
 The Netherlands

Postbus 1 | 3720 BA | Bilthoven

[redacted]

| kamer

[redacted]

T +3130

[redacted]

Present:

[redacted]

<http://www.rivm.nl/>

Committed to health and sustainability

[redacted]

[redacted]

[redacted]

[redacted]

Dubbel

5.1.2e

Dubbel